MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$5,442M
Net Income
$907M
Net Profit Margin
16.67%
EPS
$0.61
Unit: Million (M) dollars
Revenue Breakdown
US
Non Us
Revenue Breakdown
US
BSXReportable Segments-EMEA
Asia Pacific-BSXReportable Segme...
BSXReportable Segments-Latin Ame...
Revenue Breakdown
Cardiovascular
Medsurg
Impact of foreign currency fluct...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net sales
5,442
5,203
5,285
5,065
Cost of products sold (excluding amortization expense)
1,594
1,590
1,608
1,523
Gross profit
3,848
3,614
3,678
3,542
Selling, general and administrative expenses
1,803
1,781
1,833
1,741
Research and development expenses
554
516
569
514
Royalty expense
12
12
6
12
Amortization expense
233
232
228
225
Intangible asset impairment charges
0
-
-23*
0
Contingent consideration net expense (benefit)
-16
-30
7
11
Restructuring net charges (credits)
8
3
16
-8
Litigation-related net charges (credits)
76
-
218*
-
Operating expenses
2,670
2,513
2,854
2,494
Operating income (loss)
1,178
1,101
825
1,048
Interest expense
96
90
90
87
Other, net
-23
151
-35
-23
Income (loss)before income taxes
1,060
1,162
700
939
Income tax expense (benefit)
155
-176
31
183
Net income (loss)
905
1,339
670
755
Preferred stock dividends
-
-
0
-
Net income (loss) attributable to noncontrolling interests
-2
-2
-2
0
Net income (loss) attributable to boston scientific common stockholders
907
1,341
672
755
Basic EPS
0.62
0.9
0.453
0.51
Diluted EPS
0.61
0.9
0.449
0.51
Basic Average Shares
1,470,200,000
1,484,900,000
1,482,800,000
1,481,700,000
Diluted Average Shares
1,474,800,000
1,495,000,000
1,495,900,000
1,495,500,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
US
$3,426M
(6.27%↑ Y/Y)
Non Us
$2,017M
(9.80%↑ Y/Y)
Net sales
$5,442M
(7.53%↑ Y/Y)
Gross profit
$3,848M
(12.38%↑ Y/Y)
Cost of products sold
(excluding amortization...
$1,594M
(-2.63%↓ Y/Y)
Operating income (loss)
$1,178M
(43.83%↑ Y/Y)
Operating expenses
$2,670M
(2.50%↑ Y/Y)
Contingent consideration
net expense...
-$16M
(-220.00%↓ Y/Y)
Income (loss)before
income taxes
$1,060M
(12.65%↑ Y/Y)
Interest expense
$96M
(6.67%↑ Y/Y)
Other, net
-$23M
(-110.80%↓ Y/Y)
Selling, general and
administrative expenses
$1,803M
(5.07%↑ Y/Y)
Research and development
expenses
$554M
(5.32%↑ Y/Y)
Amortization expense
$233M
(3.56%↑ Y/Y)
Litigation-related net charges
(credits)
$76M
Royalty expense
$12M
(-14.29%↓ Y/Y)
Restructuring net charges
(credits)
$8M
(-90.36%↓ Y/Y)
Net income (loss)
$905M
(13.84%↑ Y/Y)
Net income (loss)
attributable to...
-$2M
(0.00%↑ Y/Y)
Income tax expense
(benefit)
$155M
(6.16%↑ Y/Y)
Net income (loss)
attributable to boston...
$907M
(13.80%↑ Y/Y)
Buy us a coffee
safari-pinned-tab-svg
BOSTON SCIENTIFIC CORP (BSX)
safari-pinned-tab-svg
BOSTON SCIENTIFIC CORP (BSX)
Show more